JULIA SUMMIT COLOMBIA 2025 Successfully Concludes in Medellín

JULIA SUMMIT COLOMBIA 2025 Successfully Concludes in Medellín

VAIM announced the successful completion of “JULIA SUMMIT COLOMBIA 2025,” an international academic symposium held in Medellín on October 15, in close collaboration with its Colombian partner.

The event was organized and hosted by VAIM’s local partner, with VAIM providing comprehensive academic and speaker support. Approximately 60 medical professionals attended the symposium, which was structured into five scientific sessions focused exclusively on Juvelook. The program featured evidence-based clinical data, theoretical lectures, and real-world cases from long-term users, reinforcing Juvelook’s efficacy, safety, and expanding clinical applications.

In addition to the lecture sessions, the program included live demonstration sessions, allowing participants to observe advanced injection techniques and gain practical insights directly from experienced clinicians. Through this collaborative academic format, the symposium significantly enhanced participants’ understanding of Juvelook and its clinical versatility.

Following JULIA Summit Colombia, AMWC LATAM 2025 was held from October 16 to 18 at the Plaza Mayor Medellín Convention Center. While VAIM did not participate directly as an exhibitor, its Colombian partner took part in the congress, conducting multiple Juvelook-related lectures and live demonstration sessions. VAIM supported these activities by providing speaker coordination and academic content, contributing to a higher scientific standard across the sessions.

Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM currently has product export contracts with 72 countries.